Seattle biotech Alpine Immune Sciences raises $91M for drug development

Alpine Immune Sciences announced it is raising approximately $91 million to continue developing two drugs through a private placement.

Frazier Life Sciences Public Fund is leading the Seattle-based biotech company’s private placement with additional support from Decheng Capital, BVF Partners, TCG X, Avidity Partners, OrbiMed, Omega Fund, and Logos Capital.

“As a long-term backer of Alpine, we are impressed by the company’s progress and their emergence as a leader in both immunology and immuno-oncology. We are pleased to lead this syndicate of strong investors and look forward to supporting the company in this next phase of growth.” said James Topper, a managing general partner of Frazier’s life sciences team.

READ THE STORY at Puget Sound Business Journal »